Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.60 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23524229 | 0.98 | PNMT (0.62) | PNMTTAAR1SLC18A2SIGMAR1CHRM2 | |
| SCHEMBL10395509 | 0.84 | PNMT (0.68) | PNMTTAAR1CHRM2SLC2A1TSHR | |
| SCHEMBL9628042 | 0.82 | MAOB (0.61) | SLC2A1 | |
| SCHEMBL7704772 | 0.81 | PNMT (0.59) | PNMTTAAR1SIGMAR1CHRM2SLC2A1 | |
| SCHEMBL1228262 | 0.81 | PNMT (0.59) | PNMTTAAR1SIGMAR1CHRM2SLC2A1 | |
| SCHEMBL777207 | 0.80 | PNMT (0.74) | PNMTTAAR1SIGMAR1CHRM2SLC6A4 | |
| SCHEMBL10518858 | 0.80 | TAAR1 (0.65) | PNMTTAAR1CHRM2SLC2A1TSHR | |
| Hydrochloric Acid SCHEMBL7714557 | 0.80 | PNMT (0.57) | PNMTTAAR1SIGMAR1CHRM2SLC2A1 | |
| SCHEMBL14655777 | 0.79 | TAAR1 (0.62) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL14655778 | 0.79 | TAAR1 (0.62) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841085-B1 | NBOME TEST | UNIV SYDNEY TECHNOLOGY (AU) | 2026-05-06 | — | — | EP | disclosed |
| WO-2024234014-A1 | SUBLINGUAL SPRAY FORMULATIONS OF PSYCHEDELICS | SPIRITUS BIOSCIENCE, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240122895-A1 | ENTACTOGEN-ASSISTED THERAPY FOR ALCOHOL USE DISORDER AND ADDICTION-RELATED CONDITIONS AND COMORBIDITIES | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2024-04-18 | — | — | US | disclosed |
| US-11761954-B2 | NBOMe test | UNIVERSITY OF TECHNOLOGY SYDNEY | 2023-09-19 | — | — | US | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2431362-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2010131669-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | PNMT 4743/4885TAAR1 1125/4885SLC18A2 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.